Navigation

Lung cancer (non-small cell) - erlotinib & gefitinib (post chemotherapy) (rev TA162, TA175) [ID620]

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (Review of TA162 and TA175)

Status: In development
Expected date of issue: June 2014
Process: MTA
Topic area:
  • Cancer
  • Respiratory
 

NICE project team

Technical Lead: Martyn Burke
Communications manager: Alice Law
Project manager:

Nicole Fisher

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 9 July 2013
1st appraisal committee meeting: 07 January 2013
2nd appraisal committee meeting: 05 March 2014
3rd appraisal committee meeting: 07 May 2014
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • AstraZeneca (gefitinib)
  • Roche Products (erlotinib)

Patient/carer groups

  • Roy Castle Lung Cancer Foundation

Professional groups

  • British Thoracic Society (Lung Cancer and Mesothelioma Working party)
  • Cancer Research UK
  • National Lung Cancer Forum for Nurses
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Health Improvement Scotland

Comparator manufacturers

  • Accord Healthcare Ltd (docetaxel) (Confidentiality agreement not signed, not participating)
  • Actavis UK (docetaxel) (Confidentiality agreement not signed, not participating)
  • Hospira UK (docetaxel) (Confidentiality agreement not signed, not participating)
  • Medac UK (docetaxel) (Confidentiality agreement not signed, not participating)
  • Sandoz (docetaxel) (Confidentiality agreement not signed, not participating)
  • Sanofi (docetaxel) (Confidentiality agreement not signed, not participating)
  • Teva UK (docetaxel) (Confidentiality agreement not signed, not participating)

Relevant research groups

  • British Thoracic Oncology Group

Assessment Group

  • Liverpool Reviews and Implementation Group (LRIG)
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • National Collaborating Centre for Cancer

Associated public health groups

  • None

Top


 

Key documents

This page was last updated: 04 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.